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Abstract
The Oregon ‘‘Death With Dignity’’ Act (DWD Act) allows a terminally ill patient with
6 months to live to ask a physician for medication to end their life. To receive the
medication, the DWD Act requires the patient to verbally request the prescription
twice 2 weeks apart as well as in writing. Patients with amyotrophic lateral sclerosis have three main barriers to using DWD: (a) the ability to communicate their informed consent as the disease progresses further, (b) the possibility of dementia
which may affect their decisional capacity, and (c) given the nature and speed of
amyotrophic lateral sclerosis, limited time is available for patients to self-administer the prescription and may rush the time line for the death. This article reviews
the current knowledge and addresses the need for adjustments to existing law and
recommendations for states considering a DWD law.
Keywords: United States, amyotrophic lateral sclerosis, death with dignity, competency, informed consent, physician-assisted suicide

Introduction
The Oregon ‘‘Death with Dignity’’ Act (DWD Act) allows physicians to prescribe medication allowing patients with a terminal illness end their lives.
For patients with amyotrophic lateral sclerosis (ALS), however, the barriers
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to using the DWD Act may be difficult to overcome. ALS, also known as Lou
Gehrig’s disease, is a degenerative disease of the nervous system which affects the brain and spinal cord (National Institute of Neurological Disorders
and Stroke [NINDS], 2013) for which no treatment or cure has been identified (Mehta et al., 2016). The degeneration and eventual death of these motor neurons effectively cuts off communication from the brain to the muscles and can lead to the loss of the ability to move, eat, speak, and eventually
breathe (NINDS, 2013). The progressive loss of function is fatal (Mehta et al.,
2016). Patients with ALS (PALS) have three main barriers to using DWD: (a)
the ability to communicate their informed consent as the disease progresses
further, (b) the possibility of dementia which may affect their decisional capacity, and (c) given the nature and speed of ALS, limited time is available
for patients to self-administer the prescription and may rush the time line
for the death. The research presented in this article will address the need
for adjustments to be made to the current law in states with DWD laws and
recommendations for other states considering a DWD law.
Death With Dignity
History of the Oregon DWD Act
The Oregon DWD Act passed by a small margin in 1994 but not without protest (Cohen-Almagor & Hartman, 2001). Groups such as the American Medical Association and the Catholic Church opposed the DWD Act, the former
due to the role the physician played in prescribing life-ending medication
and the latter due to the perceived disrespect of the gift of life (Cohen-Almagor & Hartman, 2001). After the DWD Act passed, one of the most important responses was in the form of a lawsuit filed in federal district court
which challenged the Act based on the 14th Amendment to the Constitution. The lawsuit claimed violation of due process and equal protection of
vulnerable patients who may choose to utilize physician-assisted suicide
due to coercion or undiagnosed mental disorders (Cohen-Almagor & Hartman, 2001). In 1997, the Supreme Court ruled there was no constitutional
right to assisted suicide, and the Oregon Legislature placed the measure to
repeal the Oregon DWD Act on the November 1997 ballot (Cohen-Almagor & Hartman, 2001). The citizens of Oregon voted to keep the DWD Act
in place by a wider margin than originally voted for the DWD Act in 1994
(Cohen-Almagor & Hartman, 2001).
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Requirements of the Oregon DWD Act
The Oregon DWD Act allows terminally ill patients in the state of Oregon
with a life expectancy of 6 months or less to request and receive prescriptions for self-administered life-ending medications from their physician (Cohen- Almagor & Hartman, 2001; OR. Rev. Stat. 127.800-127.995, 1999). An
important part of the law is the self-administered requirement—it does not
legalize or ‘‘authorize a physician or any other person to end a patient’s life
by lethal injection, mercy killing or active euthanasia’’ (Cohen-Almagor &
Hartman, 2001; OR. Rev. Stat. 127.800-127.995, 1999). A capable and competent resident of Oregon with a diagnosis of a terminal disease (e.g., ALS)
can request ‘‘medication for ending his or her life in a humane and dignified manner’’ (Cohen- Almagor & Hartman, 2001; OR. Rev. Stat. 127.800127.995, 1999). The DWD Act includes a provision protecting physicians from
civil and criminal liability in aiding a person in the act of committing suicide,
which outside of the DWD Act violates Oregon law (OR. Rev. Stat. 127.800127.995, 1999; Cohen-Almagor & Hartman, 2001). The DWD Act does not
require a physician to write the prescription for the lethal medication; however, if a patient requests the medication and the physician refuses, the patient does have a right to transfer care to another provider and the physician must provide the medical records to the new physician (OR. Rev. Stat.
127.800-127.995, 1999).
The DWD Act provides meticulous detail of the procedures required for
both patients and physicians under the Act (OR. Rev. Stat. 127.800-127.995,
1999). Several steps are required prior to the prescription of the life-ending medication. First, the attending physician must make the determination
that the patient is terminally ill. The terminally ill diagnosis means the disease is incurable and irreversible, and in the physician’s reasonable medical judgment, will cause the patient’s death within 6 months (OR. Rev. Stat.
127.800-127.995, 1999). The patient must make an oral request for assistance in ending their life in a humane and dignified way, at which time the
patient’s attending physician would make the determination of competency,
mental health status, and the capability of self-administering the medication (OR. Rev. Stat. 127.800-127.995, 1999). The attending physician counsels
the patient to ensure an informed decision, including advising the patient
of the risks, results of taking the medication if prescribed, and alternative
care options (e.g., hospice, palliative care). The attending physician is required to recommend the patient inform the next-of-kin of their decision
to utilize the DWD Act. Furthermore, the physician will refer the patient to
counseling if they suspect a mental health condition such as depression or
issues with the patient’s competency or capability of self-administering the
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medication (OR. Rev. Stat. 127.800-127.995, 1999). Next, the patient is required to make a request in writing, witnessed by at least one person who
is not related by blood, not the attending physician, health-care provider,
owner of a health-care facility, or entitled to any part of the patient’s estate
(OR. Rev. Stat. 127.800-127.995, 1999). The patient is referred to and seen
by a consulting physician to confirm the diagnosis and the length of survival
time calculated by the attending physician. The consulting physician verifies
the patient is competent, is capable of self-administering the lethal medication, is acting voluntarily, and has made an informed decision (OR. Rev.
Stat. 127.800-127.995, 1999). If the consulting physician feels that there is a
concern about mental health conditions (e.g., depression, dementia), they
would recommend counseling and no medication would be prescribed until the counselor determines the mental health status and competency of
the patient (OR. Rev. Stat. 127.800-127.995, 1999). The patient is required
to make a second verbal request no sooner than 15 days after the first verbal request (OR. Rev. Stat. 127.800-127.995, 1999). At that time the attending physician must offer the opportunity for the patient to rescind the original request; however, the patient may rescind the request at any point in
the process (OR. Rev. Stat. 127.800-127.995, 1999). The prescription for the
medication cannot be written any less than 15 days after the first verbal request, and no less than 48 hours after the written request has been completed (OR. Rev. Stat. 127.800-127.995, 1999). The physician then contacts
the pharmacist to inform him or her of the prescription, and once received,
the pharmacist will dispense the medication either to the patient, the attending physician, or a designated agent of the patient (OR. Rev. Stat. 127.800127.995, 1999). The patient may decide to use the medication at any time
to end their life in a humane and dignified way.
Amyotrophic Lateral Sclerosis
ALS Phenotypes and Diagnosis
ALS is rare, affecting only 5.0 per 100,000 persons per year (Mehta et al.,
2016). In limb onset ALS, the affected person has weakness in either the affected hand or foot, leading to tripping (drop foot) or difficult with grasping objects (drop wrist). Bulbar onset ALS leads to difficulties with speech
and swallowing (Kiernan et al., 2011; Muscular Dystrophy Association [MDA]
2016a; NINDS, 2013). Furthermore, there are atypical presentations including weight loss (an indicator of poor prognosis), cramping and twitching of
the muscles without weakness or wasting, unstable emotions, and frontal–
temporal dementia (Kiernan et al., 2011).
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ALS diagnosis is made by means of elimination. In addition, because of
the uncertain nature of the ALS diagnosis, there are several diagnostic categories that patients may fit into. Arguments have been made that the diagnostic criteria are too restrictive and may have poor sensitivity, limiting diagnosis in the earliest stages when patients would most likely benefit from
therapeutic intervention (Kiernan et al., 2011). Late diagnosis can prevent
the successful navigation of medical and psychosocial interventions. ALS diagnosis can be a devastating blow to both the patient and family members,
and indecision about and insensitivity of the delivery of the final diagnosis
may delay coping with and acceptance of the diagnosis (Kiernan et al., 2011).
ALS Prognosis
ALS progression is incessant, with 50% of patients dying within 30 to 36
months of diagnosis, and 20% surviving between 5 and 10 years after diagnosis (Kiernan et al., 2011). Reduced length of survival is associated with
bulbar onset, older age, and early involvement of the respiratory muscles
(Kiernan et al., 2011). Increase length of survival is associated with diagnostic delay, younger age, and limb onset (Kiernan et al., 2011). Only two
drugs, newly released Radicava and Riluzole, have been developed to treat
ALS. Riluzole is thought to extend the life span by 3 months (ALS Association, 2016).
The earliest stages of ALS often happen prior to diagnosis (MDA, 2016b).
Muscles begin to either atrophy or spasticity begins to develop, and cramps
or fasciculations begin. The patient may notice fatigue, balance problems,
slurred speech, trouble gripping objects, and trouble with tripping. As ALS
progresses into the middle stages, symptoms become more prevalent and
paralysis of muscle groups begins, while other muscles begin to weaken
and atrophy and fasciculations continue (MDA, 2016b). Contractures can
develop in unused muscles; swallowing can become more problematic and
lead to choking and difficulty eating. Greater assistance is needed; driving
is often given up and falls may occur from which the patient cannot return
to standing without assistance. The respiratory muscles begin to weaken,
leading to shortness of breath, especially when lying down. In late stage ALS,
paralysis is widespread requiring assistance for most activities and needs
(MDA, 2016b). Eating, drinking, and speech may become impossible. Respiratory muscles are compromised, which can cause sleepiness, unclear thinking, headaches, and an increase risk of pneumonia. Most deaths from ALS
are due to respiratory insufficiency leading to respiratory failure which progresses over the course of the disease (MDA, 2016b). Less commonly, death
may occur due to aspiration of food or saliva, pulmonary embolism, cardiac
arrhythmias, and malnutrition (MDA, 2016b).
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The Statement of the Problem
There is concern that the Oregon DWD Act (as well as others) may be hastening the death or unintentionally extending the life PALS due to the requirements set forth in the Act itself. The DWD Act requires that the patient
ingests the medication on their own either through swallowing the medication or through a percutaneous endoscopic gastronomy or radioscopically
inserted percutaneous tube. In addition, the DWD Act requires the patient
to verbally request the prescription for the lethal medication twice 2 weeks
apart as well as in writing in-between the two verbal requests. Furthermore,
the DWD Act requires the patient to have less than 6 months to live.
The requirements for physician-assisted suicide are difficult to meet for
PALS, who have a varied disease course and an uncertain time line to death.
PALS must rely on computer-generated speech as the disease progresses,
due to the weakening of the facial muscles, which if not successfully mastered may render the patient unable to verbally communicate their desire
for physician-assisted suicide. Furthermore, PALS lose the ability to swallow
and face progressive paralysis which can hamper both the ability to request
physician-assisted suicide in writing and self-administer the medication. The
loss of the ability to swallow and move may happen prior to the 6-month
guideline provided in the DWD Act. Moreover, PALS may develop cognitive
impairment as the disease progresses (e.g., frontotemporal dementia, language deficits), which would no longer allow them to be deemed competent to request the medication under the DWD Act. Research estimates that
cognitive impairment may develop in 35.6% to 50% of PALS over the course
of the disease (Khin, Minor, Holloway, & Pelleg, 2015). Cognitive impairment
does not necessarily mean a patient is no longer competent; however, the
multiplicative losses over the course of the disease may make the determination of competency in the last 6 months of life difficult or impossible (Khin
et al., 2015). To further complicate the determination of competency in PALS,
research indicates that physicians do not use standardized methods of assessing decision-making capacity in Alzheimer’s patients, which may indicate discrepancies in assessing competency in PALS (Khin et al., 2015; Volicer & Ganzini, 2003).
There are concerns about the desire for physician-assisted suicide regarding PALS. PALS commonly report psychosocial distress and show symptoms
of depressed mood, hopelessness, anxiety, and confusion (Connolly, Galvin,
& Hardiman, 2015; Ganzini & Block, 2002; Gill, 2004; Monforte-Royo et al.,
2011). PALS report feeling as though they are a burden to their families and
caregivers and a significant increase in loneliness as the disease progresses
(Achille & Ogloff, 2004; Monforte-Royo et al., 2011; Stutzki et al., 2014). The
feelings of depression, loneliness, isolation, anxiety, and that the patient is
a burden on their caregivers have been associated in previous research as
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increasing the ‘‘wish to hasten death’’ through the use of physician-assisted
suicide (Achille & Ogloff, 2004; Stutzki et al., 2014). Opponents of the DWD
Act believe that these feelings may hasten death unnecessarily (Ganzini &
Block, 2002).
Moreover, PALS may feel extreme anger if denied physician-assisted suicide due to suspected mental instability, resulting from the patient feeling
powerless rather than their life is valued and hampering opportunities to resolve unrelated emotional issues (Ganzini & Block, 2002). Families may feel
that the physician, acting in the role of the gatekeeper, is an insurmountable
barrier to receiving a prescription and misinterpreting their concern for the
patient as the patient being ignored or dismissed (Ganzini & Block, 2002).
Physician–patient communication may be too focused in the here and now
rather than on future needs, neglect the negative aspects of disease progression, and who the communication needs to be initiated by (e.g., neurologist,
primary care, and palliative care) may not be clear to the care team, increasing the risk the patient feels unheard (Moss et al., 1996). Physicians and insurance companies also act as gatekeepers of the treatments and equipment
desired by PALS, and fighting the system of bureaucracy to obtain needed
items may feel like an added burden to the patient and their family, increasing the desire for a hastened death (Reagan et al., 2003). Physicians further
express concerns that patients who request physician-assisted suicide later
in the disease course are doing so because of poorly managed symptoms
and fear of death (Ganzini & Block, 2002).
Previous Policy Recommendations and Alternative Solutions
In recognition of the difficulties faced by PALS, Oregon House Bill 3337
(2015) sought to modify the language of the DWD Act to extend the expected time until death from 6 months to 1 year. House Bill 3337 did not
make it out of committee. Utah, while largely copying the Oregon DWD
Act when proposing the state’s own DWD Act (Utah House Bill 391, 2015),
removed the expected time until death language and replaced it with the
phrase ‘suffering from a terminal disease; or an intractable and unbearable
illness’ (Utah House Bill 391, 2015). The Utah proposal, however, did not pass
when voted on. Opponents of the proposed changes to the Oregon DWD
Act and the Utah DWD Act felt that a 6-month time until death was an important safeguard for the patient requesting access to a prescription for lifeending medication. While unsuccessful, the bills introduced in Oregon and
Utah have highlighted important limitations of DWD laws.
In addition to legislative efforts to modify DWD policy, physicians and
others have suggested that improvements in both hospice and palliative care
should alleviate the need for the DWD Act. Physicians believe hospice and
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palliative care will allow patients to receive adequate pain control, counseling for the patient and their caregivers to alleviate fear and anxiety, and access to home care staff to relieve the perceived burden of the patient’s illness (Achille & Ogloff, 2004; Ganzini & Block, 2002; Monforte-Royo, 2011;
Moss et al., 1996; Reagan et al., 2003; Stutzki et al., 2014). Proponents of
the DWD Act disagree, as it removes the patient’s choice to have a dignified death of their choosing, rather than the unbearable suffering brought
on by terminal illness.
Policy Recommendations
While the extended time line to death, as seen in the proposed amendment to the Oregon DWD Act (2015), and the language change to ‘‘suffering from a terminal disease; or an intractable and unbearable illness’’ suggested in the proposed Utah DWD Act (Utah House Bill 391, 2015) have
not been implemented, these changes are necessary to ensure equal access for PALS to physician-assisted suicide. Given the uncertainty of ALS
progression and when the ability to speak, write, and swallow will be lost
to the PALS, ensuring adequate time to request and receive the medication
from the doctor while a patient’s health is still intact is vital for this group.
In addition, extending the time line or modifying the language of such
bills allows for patients with other conditions with uncertain progression
paths (e.g., Alzheimer’s) to use the DWD Act. Modifications may be suggested for specific disease diagnoses to leave in place safeguards for patients with terminal illness that are more predictable in nature. In addition,
conversations between lawmakers and PALS may allow lawmakers to better understand this extremely rare disease. Moreover, policy makers need
to understand ALS more thoroughly to better assess future amendments
to DWD Acts currently in place as well as DWD Acts under consideration.
For PALS, hastening death out of fear that the medication may not be selfadministrable is a real concern. Clarifying the language of DWD Acts to allow for percutaneous endoscopic gastronomy or radioscopically inserted
percutaneous tube administration, as well as the ability for the patient to
begin administering the medication and allow for a trained person to finish administering it, may allow patients fearful of missing their window for
physician-assisted suicide more peace of mind and allow for them to delay
death for additional time with their loved ones. It may also allow for additional time to provide intervention such as palliative care, home health
care, and hospice or respite care for caregivers to be put into place, possibly increasing the quality of life for PALS and decreasing the use of the
life-ending medication in this population.
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Given the issues of physician–patient communication, medical schools
need to require additional training for their staff and students on how to
discuss terminal illness and the various pathways a terminal illness may take.
For example, discussion of the typical causes of death (e.g., respiratory failure) versus the feared cause of death (e.g., choking) may allow patients to
feel more in control of their treatment course. Exploring options such as
noninvasive versus invasive ventilation, forgoing the percutaneous endoscopic gastronomy or radioscopically inserted percutaneous tube to allow
a natural death by withholding nutrition and hydration, and acknowledging
the patient’s possible desire for physician-assisted suicide versus palliative
care may allow the patient to feel more connected with their physician. The
opportunity for PALS to see their physician as a partner, rather than a gatekeeper, may in turn allow PALS to be more open to possible options for care.
Moreover, ensuring that physicians understand the patient needs, and deals
with them proactively by ordering equipment (e.g., wheelchairs, computerassisted voice programs), ahead of the point of need may help the patient
retain autonomy and control over their situation. These actions may reduce
the need for, as well as the use of, physician- assisted suicide. Physicians,
however, must be aware in the states where DWD Acts have been passed
that their patients may request physician-assisted suicide and should prepare themselves to listen to the patient’s request and handle it appropriately.
Implementing a standard assessment of cognitive abilities, thereby ensuring patients are evaluated equally by physicians, is an important aspect
of improving the DWD Act in Oregon and other states that have implemented similar laws. The use of a standardized system of evaluating competency will reduce some of the pressure felt by physicians to make the correct decisions regarding the request for life-ending medications. In turn, a
standardized method to assess competency may allow the patient to avoid
feelings of anger and allow them to work through the emotional and psychosocial issues barring them from receiving their prescriptions. Future research around ALS and DWD may need to focus on the areas of competency
more thoroughly to better understand the possible implications of competency testing and may help physicians and families better understand the
disease progression and issues of competency.
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